LTC Completes $62 Million Joint Venture Investment for Purchase of Three Skilled Nursing Centers
— Centers Operated by Partner New to LTC — WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–LTC Properties, Inc….
— Centers Operated by Partner New to LTC — WESTLAKE VILLAGE, Calif.–(BUSINESS WIRE)–LTC Properties, Inc….
SAN FRANCISCO–(BUSINESS WIRE)–Wells Fargo announced today that it has reached an agreement with the U.S….
JAKARTA, Indonesia–(BUSINESS WIRE)–#AsiaPacific–CDB Aviation, a wholly owned Irish subsidiary of China Development Bank Financial Leasing…
Alphanumeric Keypad for PIN Access FIPS 140-3 Level 3 (Pending) Certified OS- and Device-Independent Multi-PIN…
New OV08X is the industry’s only 9.2MP, 0.7-micron image sensor to provide 4K resolution for…
Supporting the data community with the first free solution to monitor data pipelines and unleash…
JumpCloud for MSPs™ Manages Identities, Access, and Devices at Scale; New Offering Delivers Easy, Frictionless…
Comprehensive characterization of phase I UV1-checkpoint inhibitor combination trial Clinical responses seen in patients with…
SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) — Shape Therapeutics Inc. (ShapeTX), the RNA technology company…
LAVAL, Québec, Sept. 12, 2022 (GLOBE NEWSWIRE) — Acasti Pharma Inc. (“Acasti” or the “Company”)…
RESEARCH TRIANGLE PARK, N.C., Sept. 12, 2022 (GLOBE NEWSWIRE) — Opus Genetics, a patient-first gene…
REDWOOD CITY, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Coherus BioSciences, Inc. (“Coherus”, Nasdaq: CHRS), today…
Phase 2 ACTIVATE trials to advance globally in metastatic patients who have progressed on available…
Patricia Carlos named Chief Regulatory, Quality, and Safety Officer Todd Yancey, MD named Senior Global…
CARLSBAD, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage…
SOUTH SAN FRANCISCO, Calif., Sept. 12, 2022 (GLOBE NEWSWIRE) — Day One Biopharmaceuticals (Nasdaq: DAWN),…
SEATTLE, Sept. 12, 2022 (GLOBE NEWSWIRE) — Adaptive Biotechnologies Corporation (Nasdaq: ADPT), a commercial stage…
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a…
– Presentation at ESMO 2022 by Collaborator, Bristol Myers Squibb –– BMS-986249 Phase 2 study…
Currently used cisplatin-based combination treatments have limited efficacy against mesothelioma, which is one of the…